Skip to main content

7 Result(s)

within Thomas Heinicke Remove this filter Oncology Remove this filter

and

  1. Article

    Open Access

    Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

    Thomas Burmeister, Aeint-Steffen Ströh, Britta Kehden, Heiko Trautmann… in Leukemia (2024)

    Download PDF (1088 KB) View Article

  2. Article

    Open Access

    Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

    A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years were allocated to the ...

    Dietger Niederwieser, Thomas Lang, Rainer Krahl, Thomas Heinicke… in Annals of Hematology (2023)

    Download PDF (3229 KB) View Article

  3. No Access

    Article

    Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters

    Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could im...

    Peter-Martin Bruch, Sascha Dietrich, Herve Finel, Ariane Boumendil… in Leukemia (2023)

  4. Article

    Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

    Thomas Heinicke, Rainer Krahl, Christoph Kahl, Michael Cross… in Annals of Hematology (2021)

    Download PDF (1176 KB) View Article

  5. Article

    Open Access

    Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

    Relapse of acute leukemia is a frequent complication with uncertain outcome and poorly defined risk factors. From 1621 patients entered into two prospective clinical trials (AML02; n = 740 and AML04; n = 881),...

    Thomas Heinicke, Rainer Krahl, Christoph Kahl, Michael Cross… in Annals of Hematology (2021)

    Download PDF (2787 KB) View Article

  6. No Access

    Article

    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

    In this phase Ib/IIa study (ClinicalTrials.gov Identifier: NCT00850382) of the German-Austrian AML Study Group (AMLSG) the multikinase inhibitor dasatinib was added to intensive induction and consolidation che...

    Peter Paschka, Richard F Schlenk, Daniela Weber, Axel Benner, Lars Bullinger… in Leukemia (2018)

  7. No Access

    Article

    Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation—a single center experience

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic neoplasm which typically presents with skin infiltrates with or without lymphadenopathy and bone marrow involvement. No standard of c...

    Thomas Heinicke, Heiko Hütten, Thomas Kalinski, Ingolf Franke… in Annals of Hematology (2015)